Amanda Morato do Canto

Dr. Amanda Morato do Canto

Department of Medical Genetics and Genomic Medicine, Faculdade de Ciencias Medicas, Unicamp, Campinas, São Paulo, Brazil
orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2014 in Plant Physiology and Biochemistry
Verified
Journal Article
Closed access
Amanda Morato do CantoAmanda Morato do Canto
Amanda Morato do Canto
PCPaulo H.O. Ceciliato
Paulo H.O. Ceciliato
BRBianca Ribeiro
Bianca Ribeiro
FMFausto Andres Ortiz - Morea
Fausto Andres Ortiz - Morea
AGAntonio Augusto Franco Garcia
Antonio Augusto Franco Garcia
DMDaniel Moura
Daniel Moura

29 September 2020 in Metabolites
Verified
Journal Article
Open access
PDF file
ADAmanda Donatti
Amanda Donatti
Amanda Morato do CantoAmanda Morato do Canto
Amanda Morato do Canto
Alexandre Barcia GodoiAlexandre Barcia Godoi
Alexandre Barcia Godoi
DRDouglas Cescon da Rosa
Douglas Cescon da Rosa
Iscia Lopes-CendesIscia Lopes-Cendes
Iscia Lopes-Cendes
There are, still, limitations to predicting the occurrence and prognosis of neurological disorders. Biomarkers are molecules that can change in different conditions, a feature that makes them potential tools to improve the diagnosis of disease, establish a prognosis, and monitor treatments. Metabolites can be used as biomarkers, and are small molecules derived from the metabolic process found in different biological media, such as tissue samples, cells, or biofluids. They can be identified using various strategies, targeted or untargeted experiments, and by different techniques, such as high-performance liquid chromatography, mass spectrometry, or nuclear magnetic resonance. In this review, we aim to discuss the current knowledge about metabolites as biomarkers for neurological disorders. We will present recent developments that show the need and the feasibility of identifying such biomarkers in different neurological disorders, as well as discuss relevant research findings in the field of metabolomics that are helping to unravel the mechanisms underlying neurological disorders. Although several relevant results have been reported in metabolomic studies in patients with neurological diseases, there is still a long way to go for the clinical use of metabolites as potential biomarkers in these disorders, and more research in the field is needed.

1 February 2018 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
WCWellington F. Campos
Wellington F. Campos
KDKeini Dressano
Keini Dressano
PCPaulo H.O. Ceciliato
Paulo H.O. Ceciliato
Juan Carlos Guerrero-AbadJuan Carlos Guerrero-Abad
Juan Carlos Guerrero-Abad
ASAparecida Leonir Silva
Aparecida Leonir Silva
DMDaniel Moura
Daniel Moura
Arabidopsis thaliana rapid alkalinization factor 1 (AtRALF1) is a small secreted peptide hormone that inhibits root growth by repressing cell expansion. Although it is known that AtRALF1 binds the plasma membrane receptor FERONIA and conveys its signals via phosphorylation, the AtRALF1 signaling pathway is largely unknown. Here, using a yeast two hybrid system to search for AtRALF1-interacting proteins in Arabidopsis, we identified calmodulin-like protein 38 (CML38) as an AtRALF1-interacting partner. We also found that CML38 and AtRALF1 are both secreted proteins that physically interact in a Ca2+- and pH-dependent manner. CML38- knockout mutants generated via T-DNA insertion were insensitive to AtRALF1, and simultaneous treatment with both AtRALF1 and CML38 proteins restored sensitivity in these mutants. Hybrid plants lacking CML38 and having high accumulation of the AtRALF1 peptide did not exhibit the characteristic short-root phenotype caused by AtRALF1 overexpression. Although CML38 was essential for AtRALF1-mediated root inhibition, it appeared not to have an effect on the AtRALF1-induced alkalinization response. Moreover, acridinium-labeling of AtRALF1 indicated that the binding of AtRALF1 to intact roots is CML38 dependent. In summary, we describe a new component of the AtRALF1 response pathway. The new component is a calmodulin-like protein that binds AtRALF1, is essential for root growth inhibition, and has no role in AtRALF1 alkalinization.

10 October 2020 in Hippocampus
Verified
Journal Article
Closed access
PDF file
Amanda Morato do CantoAmanda Morato do Canto
Amanda Morato do Canto
AMAlexandre H. B. Matos
Alexandre H. B. Matos
Alexandre Barcia GodoiAlexandre Barcia Godoi
Alexandre Barcia Godoi
AVAndré S. Vieira
André S. Vieira
BABeatriz B. Aoyama
Beatriz B. Aoyama
Iscia Lopes-CendesIscia Lopes-Cendes
Iscia Lopes-Cendes

10 March 2020 in Scientific Reports
Verified
Journal Article
Open access
PDF file
Amanda Morato do CantoAmanda Morato do Canto
Amanda Morato do Canto
AVAndré S. Vieira
André S. Vieira
AMAlexandre H.B. Matos
Alexandre H.B. Matos
BCBenilton S. Carvalho
Benilton S. Carvalho
BHBarbara Henning
Barbara Henning
Iscia Lopes-CendesIscia Lopes-Cendes
Iscia Lopes-Cendes
Mesial temporal lobe epilepsy (MTLE) is a chronic neurological disorder affecting almost 40% of adult patients with epilepsy. Hippocampal sclerosis (HS) is a common histopathological abnormality found in patients with MTLE. HS is characterised by extensive neuronal loss in different hippocampus sub-regions. In this study, we used laser microdissection-based microproteomics to determine the protein abundances in different regions and layers of the hippocampus dentate gyrus (DG) in an electric stimulation rodent model which displays classical HS damage similar to that found in patients with MTLE. Our results indicate that there are differences in the proteomic profiles of different layers (granule cell and molecular), as well as different regions, of the DG (ventral and dorsal). We have identified new signalling pathways and proteins present in specific layers and regions of the DG, such as PARK7, RACK1, and connexin 31/gap junction. We also found two major signalling pathways that are common to all layers and regions: inflammation and energy metabolism. Finally, our results highlight the utility of high-throughput microproteomics and spatial-limited isolation of tissues in the study of complex disorders to fully appreciate the large biological heterogeneity present in different cell populations within the central nervous system.

3 March 2016 in Scientific Reports
Verified
Journal Article
Open access
AVA. S. Vieira
A. S. Vieira
AMA. H. de Matos
A. H. de Matos
Amanda Morato do CantoAmanda Morato do Canto
Amanda Morato do Canto
CRC. S. Rocha
C. S. Rocha
BCBenilton Carvalho
Benilton Carvalho
Iscia Lopes-CendesIscia Lopes-Cendes
Iscia Lopes-Cendes
We report here the first complete transcriptome analysis of the dorsal (dDG) and ventral dentate gyrus (vDG) of a rat epilepsy model presenting a hippocampal lesion with a strict resemblance to classical hippocampal sclerosis (HS). We collected the dDG and vDG by laser microdissection 15 days after electrical stimulation and performed high-throughput RNA-sequencing. There were many differentially regulated genes, some of which were specific to either of the two sub-regions in stimulated animals. Gene ontology analysis indicated an enrichment of inflammation-related processes in both sub-regions and of axonal guidance and calcium signaling processes exclusively in the vDG. There was also a differential regulation of genes encoding molecules involved in synaptic function, neural electrical activity and neuropeptides in stimulated rats. The data presented here suggests, in the time point analyzed, a remarkable interaction among several molecular components which takes place in the damaged hippocampi. Furthermore, even though similar mechanisms may function in different regions of the DG, the molecular components involved seem to be region specific.